A phase 2 clinical trial, published in The New England Journal of Medicine, included 338 adults with a body mass index (BMI) of 30 or greater, or a BMI between 27 and 30, with at least one weight-related comorbidity to assess the efficacy and benefits of retatrutide
March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD
You typically start at 2.5 mg weekly and move up to 5 mg, 10 mg, or 15 mg weekly, depending on your response to the medication and tolerance of side effects
Theyre being marketed asand, truly, you know, prescribed, tooas a lifelong treatment
I wouldnt refer to them all as identical
They may reduce: Cardiovascular issues Sleep apnea and other breathing problems High blood pressure Alcohol depedency Kidney and liver disease Some types of cancer Of course, although both Ozempic and Wegovy are semaglutides, its important to note that they themselves are already approved for separate conditions
